menu_open Columnists
Cara O’Neill, Opinion Contributor

Cara O’Neill, Opinion Contributor

The Hill

We use cookies to provide some features and experiences in QOSHE

More information  .  Close

Worth the risk: FDA must move more quickly on treatments for rare diseases

The first few months of 2025 brought hope to the rare disease community. Food and Drug Administration leadership promised transparency and increased...

26.08.2025 4

The Hill

Cara O’Neill, Opinion Contributor